IP is essential, and should be used to improve access #bio2012

In the Scientific American Worldview panel, Biocon’s Kiran Mazumdar Shaw opined on intellectual property in biotechnology — IP is essential for biotechnology, and should be used to improve access rather than to drive high prices. She elaborated that improving access with affordable medicines can yield higher profits than serving smaller markets with higher prices.

   No Comments yet

    Do NOT follow this link or you will be banned from the site!
    Get email updates

    Get new actionable insights and updates from BiotechBlog